Please assess the completion status of the following clinical trial:

Trial Title: Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of PTSD, as derived from the Clinician-Administered PTSD Scale (CAPS)~* Stabilized on any necessary medications for at least 4 weeks prior to study entry~* Score of greater than 4 on the CAPS Recurrent Distressing Dreams item (maximum score of 8)~* Score of greater than 4 on the CAPS Difficulty Falling or Staying Asleep item (maximum score of 8)~* Agrees to use an effective form of contraception throughout the study~Exclusion Criteria:~* Any acute or significant chronic medical illness~* Any unstable medical condition~* Unstable angina, recent heart attack, history of congestive heart failure, pre-existing hypotension (systolic blood pressure less than 110 mm Hg), or orthostatic hypotension~* Insulin-dependent diabetes~* Chronic kidney or liver failure~* Pancreatitis or gout~* Meniere's disease, benign positional vertigo, or narcolepsy~* Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist~* Currently taking another alpha-1 antagonist agent~* Pregnant~* DSM-IV diagnosis of cognitive disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or other psychotic disorder~* Current delirium~* Active substance dependence disorder within 3 months of study entry~* Current substance use other than alcohol (no more than 2 drinks per day)~* Severe psychiatric instability or situational life crises, including evidence of suicidal or homicidal ideation~* Currently taking any other psychotropic medication (e.g., antidepressants, benzodiazepines, anti-convulsants, anti-psychotics, sedating antihistamines, sedatives/hypnotics (exclusionary medications will be discontinued and participants will undergo a 2-week washout period before baseline assessments)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive treatment with prazosin plus psychotherapy
- 2 (Type: PLACEBO_COMPARATOR): Participants will receive treatment with placebo plus psychotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).